pharma · Advanced Solid Tumors · Advanced Solid Tumor · MDNAF
Medicenna Therapeutics
Medicenna Therapeutics is a pharma organization headquartered in Toronto, CA. It trades on NYSE under ticker MDNAF. Primary therapeutic focus areas include Advanced Solid Tumors, Advanced Solid Tumor, Glioblastoma. NovaP
Toronto, CA HQ
24 Employees
Public company Type
MDNAF · NYSE Ticker
Company details
- Status
- Public
- HQ
- Toronto, CA
- Employees
- 24
- Programs
- 3
- Drugs
- 3
- Patents
- 9
MDNA55
Phase 2 · small molecule · Glioblastoma
MDNA55 for Glioblastoma is a Phase 2 program (small_molecule) at Medicenna Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MDNA55-05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Medicenna Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Glioblastoma
- Status
- completed
- Trials
- 1